The role of statistics in the era of big data: Electronic health records for healthcare research by Sharples, Linda D
LSHTM Research Online
Sharples, LD; (2018) The role of statistics in the era of big data: Electronic health records for
healthcare research. Statistics & probability letters, 136. pp. 105-110. ISSN 0167-7152 DOI:
https://doi.org/10.1016/j.spl.2018.02.044
Downloaded from: http://researchonline.lshtm.ac.uk/4646897/
DOI: https://doi.org/10.1016/j.spl.2018.02.044
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
https://researchonline.lshtm.ac.uk
Accepted Manuscript
The role of statistics in the era of big data: Electronic health records for
healthcare research
Linda D. Sharples
PII: S0167-7152(18)30089-0
DOI: https://doi.org/10.1016/j.spl.2018.02.044
Reference: STAPRO 8166
To appear in: Statistics and Probability Letters
Please cite this article as: Sharples L.D., The role of statistics in the era of big data: Electronic
health records for healthcare research. Statistics and Probability Letters (2018),
https://doi.org/10.1016/j.spl.2018.02.044
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form.
Please note that during the production process errors may be discovered which could affect the
content, and all legal disclaimers that apply to the journal pertain.
1 
 
The role of statistics in the era of big data: electronic health records for healthcare research 
Linda D Sharples, Department of Medical Statistics, London School of Hygiene & Tropical Medicine, 
London WC1E 7HT; Linda.Sharples@lshtm.ac.uk 
Abstract 
The transferring of medical records into huge electronic databases has opened up opportunities for 
research but requires attention to data quality, study design and issues of bias and confounding. 
Introduction 
Traditionally, statistical analysis in healthcare was limited by the numbers of patients available and 
difficulty in combining and reconciling information from different sources. Huge investment in 
transferring medical notes into electronic health records (EHR) and provision of efficient software 
have largely overcome these limitations. New data sources offer opportunities to gain deeper insight 
into biological mechanisms, effectiveness of healthcare delivery and medical therapies, based on real-
time availability and low-cost data.  EHR can enhance quality and/or efficiency of evaluating quality 
of care, designing improvements, monitoring safety and effectiveness of therapies when applied to a 
population, and assessment of cost effectiveness. Studies of patient heterogeneity in treatment 
allocation and response may bring stratified medicine closer. 
The reliability of statistical analysis of EHR depends on the type of database used and how it arose 
(e.g. administrative, disease registry). Many databases now have national coverage, are population-
based, longitudinal and linkable to other databases. Others depend on some sampling process, detailed 
data collection is restricted to a short time interval, possibly surrounding an event or a health 
intervention, or both; these selection procedures must be taken into account in analysis and 
interpretation. Moreover, different data sources will have different levels of quality, consistency of 
recording and definitions, completeness, levels of detail and speed of accumulation. This paper 
discusses practical and statistical issues surrounding the use and analysis of routinely-collected EHR.  
Data access and quality 
To protect patient confidentiality and data security, the body that collates, links and provides the 
dataset (data guardian) is usually separate from the researchers who analyse it. It is essential to work 
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with data guardians to understand the final dataset, assess risk of bias and ensure that it is produced on 
time and with minimum cost. Co-opting data guardian staff onto the project team gives them a stake 
in the work and fosters a culture of finding solutions to information governance issues.   
Data quality is fundamental to any statistical analysis and is particularly important for EHR, in which 
selective sampling and imperfect recording may result in amplification of bias. The size and 
complexity of existing datasets means that post hoc identification of changes in data definitions can be 
difficult.  
Some perceived data quality issues are highlighted in panel A; none are specific to EHR. However, 
with very large databases and the potential for multiple outcomes and (correlated) independent 
variables, commonly used methods for identifying and accommodating inaccurate data can be 
cumbersome. New methods for visualization to address this issue and guidance on automated quality 
assessment would be welcome. For databases that include patient-level longitudinal measurements, 
mixed-effects methods that iterate between fitting and outlier identification/removal have been 
investigated and applied to primary care data (Welch et al., 2014). The utility of these methods in 
other settings remains to be investigated, as does the transferability of methods developed for risk-
based monitoring in multi-centre trials. (Hurley et al., 2016) 
For data fields that are not recorded, it may be possible to impute missing data under an assumption of 
missing at random, conditional on observed fields.(Carpenter and Kenward, 2013) If data are not 
likely to be missing at random, it is important to work with data guardians to understand the sampling 
processes and investigate reasons for missing data, although with large datasets this may be 
computationally intensive. 
In traditional cohort studies and clinical trials, the sampling process is usually known and a joint 
model for sampling and medical condition can be constructed. However, any dataset arising from 
EHR may be incomplete due to selective sampling, inability to fully link data sources or some other 
unknown systematic process. Whilst close collaboration with data guardians will provide insight into 
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linkage problems, other issues may remain unclear. The extent of bias that may be introduced due to 
incomplete sampling deserves further investigation. 
Data linkage 
Linking of two or more datasets is a key issue. The ability to construct the complete patient care 
pathway would provide great potential to evaluate care quality and treatment decisions on short and 
long-term outcomes.  However, data security is a concern, and data guardians for different datasets 
may be different. This implies a need for very clear specification of the linkage and associated data 
processing protocols. 
Cleaning of datasets prior to linking is crucial to maximise the likelihood of finding matches. High 
sensitivity and specificity of database linking avoids some biases, although in practice, the trade-off 
between sensitivity and specificity will depend on specific applications. For example, large 
population-based EHR databases have potential for study of rare diseases, for which sensitivity of 
matching is extremely important, as loss of even a small number of cases would have a serious impact 
on power. In this case, highly sensitive (probabilistic) methods are attractive. 
The two main types of data linkage in common use, deterministic (rule-based) and probabilistic 
(score-based) linkage, each with a number of versions, were developed over 50 years ago and have 
been described in detail. (Winkler, 2006, Dusetzina et al., 2014, Harron et al., 2015) Reporting of 
linking methods in journal submissions is now expected and an extension of the STROBE statement 
for observational studies that use linked databases (RECORD) is established. (Benchimol et al., 2015) 
The simplicity and efficiency of deterministic linkage is attractive for large databases, but may result 
in poor sensitivity, particularly if data quality is poor. (Zhu et al., 2015) The poorer performance may 
be amplified if more than two datasets are to be linked. Probabilistic linkage methods are often 
reported to have better performance, especially if data quality is poor, important identifiers are not 
available and/or matching on alphanumeric fields is required, but they have the added problem of 
choosing matching thresholds, and computation time may be prohibitive when several datasets have 
to be matched. (Zhu et al., 2015) Methods for improving the match accuracy in deterministic linking 
and strategies for increasing the speed of probabilistic linkage, would increase use of these methods 
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and may reduce bias, particularly for large datasets. However, the threshold for data matching will 
depend on the data quality.  
Assessment of the quality of linkage is important. There are a number of methods available to assess 
this quality, which are reviewed elsewhere. (Harron et al., 2015)  
A range of sophisticated linkage algorithms exist. For example, EM algorithms using matching 
weights, (Belin and Rubin, 1995) distance-based algorithms, (Herranz et al., 2015) and prior-informed 
imputation, (Harron et al., 2014) have all been investigated. Others have explored machine learning 
methods, which have potential for very large linkage problems (Elfeky et al., 2003) and further 
guidance on the value of these methods is needed. 
Analysis using observational study design 
Although randomised controlled trials remain the gold standard for establishing causal relationships 
between interventions and outcomes, EHR, along with modern causal inference methods, can provide 
information when randomisation is not practical or ethical. EHR databases are often population-based, 
conferring strong external validity. On the other hand, naïve EHR analyses may exacerbate bias and 
confounding, which are common in observational research. Requirements for sound analysis and 
statistical themes to be re-assessed in this context are discussed below. 
The need for protocols 
The way in which the dataset has been constructed is crucial; it should be made explicit and should be 
reflected in the statistical design and analysis of the study. Statisticians are concerned about how the 
population of interest is defined and sampled, how an intervention or exposure is defined, the 
definition of the impact of exposures and crucially, the structure of the model that links these 
components. These issues remain fundamental to analysis and interpretation. Apart from good registry 
design, a key issue is consistency of data definition across data-entry sites and through time, which 
relies on strong central management and co-ordination. Although these concerns may be 
straightforward to manage across similar sites, say primary care centres, when combined with 
secondary care or other databases, consistent definitions may be difficult to achieve. For example, 
diagnosis of an infection may be based on a serum marker in primary care but a tissue sample in 
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secondary care.  Research into methods for detection and accommodation of conflicts between data 
sources would improve confidence in statistical analyses. 
Adjustment for confounding in observational studies 
In recent years substantial contributions to the methodology for adjustment for bias due to 
confounding have been made, and include propensity scoring and similar methods, and instrumental 
variables approaches including Mendelian randomisation (Pearl, 2016, Stuart, 2010, Williamson et al., 
2012, Smith and Ebrahim, 2003) Perhaps the most widely used methods in healthcare settings are 
propensity score methods. (Stuart, 2010) The conceptual simplicity of matching methods and their 
straightforward assumptions may explain their more frequent use in health research. However, the 
assumption that all important factors are included in the propensity score is often given scant 
attention. Whilst propensity score methods will be extremely useful if the datasets are largely 
complete and linkage error is low, they may be complicated if many covariates are required for the 
propensity score (potential for missing covariates) or more than two data sources are to be linked 
(potential for linkage error). There are strategies for high-dimensional propensity scores in a medical 
setting (Schneeweiss et al., 2009), and missing data methods are established. (Carpenter and 
Kenward, 2013) However, in EHR confounding and missing covariates must be tackled 
simultaneously, for which more methodological work is required. (Leyrat et al., 2017)  
Other flexible, but more complicated, methods for dealing with confounding are available including 
G-computation, (Robins, 1986), inverse-probability-of-treatment (IPTW) estimators (Austin and 
Stuart, 2015), and doubly robust methods such as targeted maximum likelihood estimation (Targeted 
MLE). (Gruber and van der Laan, 2009) Targeted MLE is attractive in the context of EHR since it 
focuses on minimising bias for key parameters, treating all others as nuisance parameters. Such 
targeted inference, if it can be made accessible, may have a place in the analysis of EHR. More 
generally, a greater understanding of the utility, advantages and disadvantages of more complex 
causal methodologies is needed. Validation of sophisticated causal methods in this context is 
challenging. Where possible attention should focus on efficiency of implementation if the methods are 
to make a difference in practice. 
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Multiple dimensions 
The complexity of EHR opens up opportunities to investigate multiple dimensions of healthcare. 
Multi-level models: Hierarchies (e.g. patients within hospitals within regions) within EHR introduce 
complicated correlation structures. Failure to recognise this may result in inaccuracy in both point 
estimates and measures of uncertainty, especially if statistical units vary in size. Statistical analysis of 
EHR requires exploratory methods to investigate clustering of statistical units, via hierarchical and 
cross-classified models, (Goldstein, 1987) and to identify latent constructs for further investigation.  
Multi-state models: Patient monitoring through time for repeated events, possibly of different levels 
of severity is made possible by EHR. For example, multi-state models can be constructed to 
simultaneously predict survival, time to the next hospitalisation and total time spent in hospital, 
incorporating fixed and time varying covariates. (Ieva et al., 2017) Open questions pertain to the 
choice of sojourn time distribution (parametric or semi-parametric intensities), effects of linkage 
errors, the level and nature of missing records, assessment of model fit and computational issues. 
Although software packages for fitting interval censored (msm) and fully observed (mstate, flexsurv) 
data improve accessibility of methods, their utility for analysis of EHR and the accuracy of 
approximate methods need investigation. (Jackson, 2011, de Wreede et al., 2011, Jackson, 2016) 
Multivariate models: The richness of EHR allows for multiple correlated variables to be investigated 
simultaneously. As the population ages, the number of people with multiple, possibly related, 
comorbidities will increase. These co-morbidities may be treated as vectors of response variables or 
correlated independent predictors, depending on the research question. EHR can provide important 
information on strategies for the joint management of multiple comorbidities. The size of EHR 
databases may also allow investigation of interactions between comorbidities. In this context it is 
important to understand the causal pathway. For example, when assessing the joint effects of smoking 
and COPD on lung cancer risk, one might wish to model smoking as an explanatory variable for 
COPD and both as explanatory variables for lung cancer. Care is needed in choosing the statistical 
model, including the covariance structure. 
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Generalisation of clinical trial results 
A major benefit of EHR is the ability to assess how interventions and exposures impact patients in a 
general health setting. Participants in RCTs are selected to a greater or lesser extent and may differ 
from the target population to be treated, so that expected treatment effects may differ. Using EHR and 
propensity matching methods, the treatment effect in the target population can be evaluated, so that 
prescribing practices can be optimised. (Stuart, 2011)   
The regression discontinuity design (RDD) has been used where treatments are applied according to a 
fixed rule and results from RCTs are not consistently replicated in routine healthcare. (Geneletti et al., 
2015) For example, statins are recommended when risk of a cardiovascular event exceeds a particular 
threshold. Patients who have a risk prediction close to the threshold are considered approximately 
comparable and those just above the threshold are compared with those below.  (Geneletti et al., 2015) 
These designs applied to data from EHR can identify the extent of compliance with clinical guidance, 
reasons for non-compliance, and the treatment effect in the target population. Practical guidance is 
needed on application of these methods, the window within which patients are considered comparable 
and the estimation approach. In particular, for patients who are likely to be under-represented in trials, 
(e.g. older people, rare diseases), these methods provide an indication of the likely value of treatment.  
General evidence synthesis 
General evidence synthesis describes the combination of data sources in a statistical model and has 
applications in, for example, health economics and epidemic modelling. In the UK, healthcare 
decisions are assessed by the National Institute of Health and Care Excellence, based on decision 
models that typically combine RCTs or meta-analyses of RCTs (robust treatment effects), 
observational studies (non-trial outcomes), disease registries (longer-term disease-related outcomes, 
stratification for baseline risk), hospital records (resource use) and population statistics (death from 
non-related causes) (NICE, 2013). The improvement in availability and quality of EHR has conferred 
an increase in quality of these analyses. However, results, and therefore policy decisions, are sensitive 
to the structure of the decision model, and it is difficult to give general advice on this structural 
uncertainty. (Jackson et al., 2011) Moreover, information on a parameter in the model can come from 
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more than one database, which sometimes results in conflicts and difficulty in model fitting. 
Statistical and computational methods that identify and accommodate conflicts are required. 
Randomised trials 
Despite the benefits of EHR they are not likely to obviate the need for tightly controlled randomised 
studies. Of course RCTs have limitations: obtaining funding and regulatory approvals is challenging 
and time consuming; they often represent selected populations and unrealistic practice (limited 
external validity); difficulties in patient recruitment and retention are well documented; follow-up is 
short-term; data collection is limited; most compare a single experimental treatment with a control.  
(Olsen et al., 2013, Young, 2010).  However, well designed and conducted RCTs provide evidence of 
causal effects of interventions. EHR may improve efficiency of design and analysis of RCTs.  
In the UK, the National Institute for Health Research (NIHR) have issued calls for efficient trial 
designs that both replicate conditions in the UK National Health Service and maintain randomised 
treatment allocation. In this context, EHR can be used in design of trials, providing objective 
information on population characteristics, inclusion and exclusion criteria, recruitment rates and 
possibly attrition rates. Interrogation of existing databases would allow realistic estimation of numbers 
of available patients and of clinicians/treatment centres that might contribute cases. National mortality 
databases have long been used to define or verify survival outcomes for trials; EHR, especially 
disease registries, include a range of routinely-recorded outcomes (e.g. hospital admissions, 
myocardial infarction, cancer diagnosis). EHR may be used to assess the potential effect of an 
intervention, providing a more evidence-based sample size calculation.  If a sufficiently mature and 
high quality database exists, trial outcomes may be wholly or partially available, thereby reducing 
resources required for patient follow-up. Further, EHR can enable health economists to capture all 
calls on health resources in the trial arms. 
Several groups have advocated innovative trial designs embedding randomised trials within an 
existing large cohort. (Relton et al., 2010). For example, in the cohort multiple RCT a cohort is 
constructed, perhaps around an initial RCT, and patients are approached and consented to data follow-
up. As new treatments emerge a sample of enrolled patients are selected using a random process and 
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offered the new treatment. Routinely collected outcome data are compared between selected and non-
selected patients. This design retains random allocation, via random selection, thereby providing 
unbiased treatment effect estimates, minimises selection bias and retains the characteristics of the 
target population. It is possible to achieve high recruitment rates at lower cost than conventional 
RCTS, as demonstrated in the TASTE trial. (Frobert et al., 2010) Although the scope and success of 
such designs is yet to be established they are worth pursuing for a number of reasons. Importantly, 
they promote the implementation of successful new treatments since their utility in practice will have 
been established. Open research questions surround treatment of missing data, maintaining data 
quality, the reaction of patients in the control group to not being told they are in the trial and 
acceptability of the design to patients, clinicians, sponsors, funders and regulators. 
Concluding remarks 
Investment in EHR has resulted in opportunities for insight into healthcare provision, epidemiology 
and evaluation of treatments. This paper gives a flavour of the issues that arise in EHR but is not a 
comprehensive review; areas such as data mining, supervised and unsupervised learning and 
sophisticated prediction methods, and a wide-ranging discussion of causal inference methods, have 
been left to others. The complexity of data access, linkage and database quality and design suggests 
that statistical analysis and study design, will be challenging.  
Panel A Data quality issues 
(i) Inaccurate data records. Since EHR are rarely constructed for research it is crucial to 
understand how the data fields have been defined and recorded. Data regularly and routinely 
change over time. Extreme records are easy to spot but other inaccuracies are not. Comparisons of 
summary statistics between different groups, examination of correlation structures and within-
patient changes can highlight poor data quality. Consideration should be given to the life time (use-
by date) of the database. 
(ii) Complete sampling but some data fields not recorded. For some data fields, age or sex 
say, missing records are obvious. For other fields, say asthma attack, an empty field may mean that 
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no asthma attack took place, or it was simply not recorded. Bias and imprecision in estimates of 
asthma prevalence and treatment effects may result, and it is difficult to detect without external 
information. 
(iii) Incomplete sampling. If a patient only seeks medical help when sick or if the data linking 
processes are inaccurate, the sampling process and the clinical situation under investigation will not 
be independent of each other. (Gruger et al., 1991, Zeng et al., 2015) 
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